Skip to main content

Impel NeuroPharma, Inc. (IMPL)

NASDAQ: IMPL · IEX Real-Time Price · USD
10.06
+0.12 (1.21%)
After-hours:Oct 22, 2021 7:59 PM EDT
9.94
-0.40 (-3.87%)
At close: Oct 22, 4:00 PM
Market Cap194.90M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out14.12M
EPS (ttm)-12.37
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume163,494
Open10.23
Previous Close10.34
Day's Range9.73 - 10.23
52-Week Range6.90 - 34.75
Betan/a
AnalystsStrong Buy
Price Target48.00 (+382.9%)
Est. Earnings DateNov 11, 2021

About IMPL

Impel NeuroPharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is TRUDHESA, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodop...

IndustryBiotechnology
IPO DateApr 23, 2021
CEOMichael Hite
Employees59
Stock ExchangeNASDAQ
Ticker SymbolIMPL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for IMPL stock is "Strong Buy." The 12-month stock price forecast is 48.00, which is an increase of 382.90% from the latest price.

Price Target
$48.00
(382.90% upside)
Analyst Consensus: Strong Buy

News

Phil Announces Partnership with Impel NeuroPharma in Support of Trudhesa™ (dihydroergotamine mesylate) Nasal Spray fo...

SAN FRANCISCO, Sept. 29, 2021 /PRNewswire/ -- Phil, Inc. announces partnership with Impel NeuroPharma, Inc. (NASDAQ: IMPL) in support of Trudhesa™ (dihydroergotamine mesylate) nasal spray (0.725 mg per ...

3 weeks ago - PRNewsWire

Carepoint Pharmacy Selected by Impel NeuroPharma as a Digital Pharmacy Partner for the Launch of Trudhesa™ (Dihydroer...

SCHAUMBURG, Ill., Sept. 28, 2021 /PRNewswire/ -- Carepoint Pharmacy announces that it will partner  with Impel NeuroPharma, Inc. (NASDAQ: IMPL)  to begin dispensing Trudhesa™ (dihydroergotamine mesylate...

3 weeks ago - PRNewsWire

Impel NeuroPharma Announces Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray is Now Available for Prescription for ...

Trudhesa is the First and Only Therapeutic to Use POD® Technology to Deliver Dihydroergotamine Mesylate (DHE)—a Proven, Well-Established Therapeutic—to the Vascular-Rich Upper Nasal Space

3 weeks ago - GlobeNewsWire

Why Impel NeuroPharma Dived by 24% Today

For investors, the company's price for a new share issue isn't right.

1 month ago - The Motley Fool

Impel NeuroPharma To Raise $45M Via Equity Offering

Impel NeuroPharma Inc's (NASDAQ: IMPL) has priced its previously announced underwritten public offering of 3 million shares at $15.00 per share for gross proceeds of $45 million. The offer price represe...

1 month ago - Benzinga

Impel NeuroPharma Announces Pricing of $45.0 Million Public Offering

SEATTLE, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases wi...

1 month ago - GlobeNewsWire

Why Impel NeuroPharma Stock Blasted 27% Higher Thursday

A big sell-off in the stock is followed by a sudden bull rush, days after the company wins its first FDA approval.

1 month ago - The Motley Fool

Why Impel NeuroPharma Gained 17% Today Then Faded

The FDA approval celebration is over, and the real work of selling is about to begin.

1 month ago - The Motley Fool

Impel NeuroPharma Announces Launch of Proposed Public Offering

SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases wi...

1 month ago - GlobeNewsWire

Impel (IMPL) Gets FDA Nod for Trudhesa in Migraine Treatment

The FDA approves Impel's (IMPL) Trudhesa nasal spray for the acute treatment of migraine with or without aura in adults.

1 month ago - Zacks Investment Research

This analyst raised his price target on Impel NeuroPharma by more than 50%

Impel NeuroPharma Inc. (NASDAQ: IMPL) secured U.S. FDA approval for its Trudhesa nasal spray as an acute treatment of migraine in adults (with or without aura). Shares of the company opened more than 40...

1 month ago - Invezz

Cowen Beefs Up Target Price For This Medical Device Firm

Cowen has raised Impel NeuroPharma Inc's (NASDAQ:IMPL) price target to $55 from $35, with an Outperform rating, after the FDA approved Trudhesa for the acute treatment of migraine. The analyst sees more...

1 month ago - Benzinga

Why Impel NeuroPharma Stock Is Soaring Today

The company's nasal spray got a green light from the FDA to treat migraine headaches.

1 month ago - The Motley Fool

FDA Gives Nod To Nasal Spray Migraine Treatment From Impel NeuroPharma; Stock Jumps

The FDA has approved Impel NeuroPharma Inc's (NASDAQ: IMPL) Trudhesa (dihydroergotamine mesylate) nasal spray for the acute treatment of migraine with or without aura in adults.  Using Impel's Precision...

1 month ago - Benzinga

Impel NeuroPharma Announces U.S. FDA Approval of TRUDHESA™ (Dihydroergotamine Mesylate) Nasal Spray for the Acute Tre...

TRUDHESA Is the First and Only Therapeutic to Use POD technology to Deliver Dihydroergotamine Mesylate (DHE) to the Vascular-Rich Upper Nasal Space

1 month ago - GlobeNewsWire

Impel NeuroPharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update

TRUDHESA™ New Drug Application (NDA) Under Review by U.S. Food & Drug Administration (FDA) with PDUFA Target Action Date of September 6, 2021

2 months ago - GlobeNewsWire

Impel NeuroPharma to Report Second Quarter 2021 Financial Results on Monday, August 16, 2021

SEATTLE, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for...

2 months ago - GlobeNewsWire

Impel NeuroPharma Announces Publication of Pivotal Phase 3, Open-Label Stop 301 Study of INP104 (TRUDHESA™) for Treat...

Study Shows TRUDHESA™ Was Well Tolerated and Delivered Rapid, Consistent Symptom Relief

2 months ago - GlobeNewsWire

Impel NeuroPharma to Present at the 2021 Wedbush Pacgrow Virtual Healthcare Conference

SEATTLE, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for...

2 months ago - GlobeNewsWire

Impel NeuroPharma Enters Into a $50 Million Debt Financing Agreement With Oxford Finance LLC and Silicon Valley Bank

SEATTLE, July 07, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (Impel), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patien...

3 months ago - GlobeNewsWire

Impel NeuroPharma Announces First Quarter 2021 Financial Results and Provides Business Update

– Completed successful IPO raising approximately $80.0 million in gross proceeds – – NDA for TRUDHESA for treatment of acute migraine accepted for review by FDA; PDUFA date of September 6, 2021 – – Stre...

4 months ago - GlobeNewsWire

Impel NeuroPharma Launches Reroute Migraine Relief, Educational Initiative That Brings to Life the Underrecognized Co...

Initiative Features Artwork from Internationally Renowned Artist Ed Fairburn, Specially Developed to Illustrate the Complexities of Migraine Initiative Features Artwork from Internationally Renowned Art...

5 months ago - GlobeNewsWire

Impel Neuropharma raises $80M in Washington state's first IPO of 2021

The news: Seattle-based biotech company Impel NeuroPharma raised $80 million in its initial public offering and will begin trading on the NASDAQ Friday.

5 months ago - GeekWire

Impel NeuroPharma Announces Pricing of $80.0 Million Initial Public Offering

SEATTLE, April 22, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (Impel), a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformati...

6 months ago - GlobeNewsWire